Peter J. Fromen
Chief Executive Officer bei Biomodal Ltd.
Profil
Peter J.
Fromen holds the position of Chief Executive Officer & Director at Cambridge Epigenetix Ltd.
and Chief Executive Officer & Director at Cambridge Epigenetix Ltd.
In the past he occupied the position of Senior Director-Investor Relations at Illumina, Inc. and Chief Commercial Officer at Pacific Biosciences of California, Inc.
Peter J.
Fromen received an undergraduate degree from Kenyon College and an MBA from W.P.
Carey School of Business.
Aktive Positionen von Peter J. Fromen
| Unternehmen | Position | Beginn |
|---|---|---|
Biomodal Ltd.
 Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom. | Chief Executive Officer | 18.07.2022 |
Ehemalige bekannte Positionen von Peter J. Fromen
| Unternehmen | Position | Ende |
|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Corporate Officer/Principal | 20.05.2022 |
| ILLUMINA, INC. | Investor Relations Contact | - |
Ausbildung von Peter J. Fromen
| Kenyon College | Undergraduate Degree |
| W.P. Carey School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ILLUMINA, INC. | Health Technology |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Biomodal Ltd.
Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
